A 10-valent pneumococcal conjugate vaccine is up to 100% effective in preventing vaccine-type invasive disease in young children, according to an industry-sponsored study in the Lancet. The PHiD-CV10 vaccine, marketed in Europe as Synflorix, contains 10 serotype-specific polysaccharides conjugated to Haemophilus influenzae protein D, tetanus toxoid, and diphtheria toxoid carriers.

Researchers randomized nearly 46,000 Finnish children aged 6 weeks to 18 months to receive the pneumococcal vaccine or a control vaccine. Vaccination schedules depended on the patient’s age and included either two or three primary vaccinations at varying intervals, with or without a booster dose.

During over 2 years’ follow-up, there were 13 cases of vaccine-type invasive pneumococcal disease. The vaccine’s efficacy ranged from 92% to 100%, depending on the schedule followed. No safety concerns emerged.

A commentator says that the results “provide confirmatory, conclusive evidence about the vaccine’s benefits against invasive disease.”

Source: Lancet